var data={"title":"Varenicline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Varenicline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/227574?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=varenicline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Varenicline: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975238\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Chantix;</li>\n      <li>Chantix Continuing Month Pak;</li>\n      <li>Chantix Starting Month Pak</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4104776\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Champix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975262\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Partial Nicotine Agonist;</li>\n      <li>\n        Smoking Cessation Aid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975291\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Smoking cessation:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Days 1 to 3: 0.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Days 4 to 7: 0.5 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Maintenance (&ge; Day 8): 1 mg twice daily for 11 weeks; may consider a temporary or permanent dose reduction if usual dose is not tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Start 1 week before target quit date. Alternatively, patients may consider setting a quit date up to 35 days after initiation of varenicline (some data suggest that an extended pretreatment regimen may result in higher abstinence rates [Hajek 2011]). For patients who are sure that they are not able or willing to quit abruptly, begin treatment with vareniciline and reduce smoking by 50% from baseline within the first 4 weeks, by an additional 50% in the next 4 weeks, and continue reducing with the goal of complete abstinence by 12 weeks. If patient successfully quits smoking at the end of the 12 weeks, may continue for another 12 weeks to help maintain success. Patients who are motivated to quit and do not succeed in stopping smoking during prior therapy, or who relapse after treatment, should be encouraged to make another attempt with varenicline once factors contributing to the failed attempt have been identified and addressed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975292\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975293\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">CrCl &lt;30 mL/minute: Initiate: 0.5 mg once daily; maximum dose: 0.5 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">End-stage renal disease (ESRD) (receiving hemodialysis): Maximum dose: 0.5 mg once daily </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975294\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975295\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Patients who cannot tolerate adverse events may require temporary (or permanent) reduction in dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975300\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chantix: 0.5 mg, 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chantix Continuing Month Pak: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chantix Starting Month Pak: 0.5 mg x 11 &amp; 1 mg x 42</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975240\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46146256\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Champix: 0.5 mg, 1 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7875058\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021928s040lbl.pdf#page=19&amp;token=Pnic8sB+7aUosAgp7fpFzZzqVgQ3MfOsN1G3ONTVF60XNW5PcHnBMNwCy+3TE1kE818TfHBV+qLPn02ipdVcWtCvM48DeRK9vnwkWXEfE0ZbcjGQ288qlUx4WkhAHpzY&amp;TOPIC_ID=10339\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021928s040lbl.pdf#page=19</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975297\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Administer after eating and with a full glass of water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975263\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Smoking cessation:</b> As an aid to smoking cessation treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975271\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (12% to 19%), insomnia (9% to 19%), abnormal dreams (8% to 13%), irritability (11%), suicidal ideation (11%), depression (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (16% to 40%), vomiting (5% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris (4%), chest pain (3%), peripheral edema (2%), myocardial infarction (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (8%), malaise (7%), agitation (5% to 7%), sleep disorder (3% to 5%), tension (4%), drowsiness (3%), hostility (2% to 3%), lethargy (1% to 2%), nightmares (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Flatulence (6% to 9%), constipation (5% to 8%), dysgeusia (5% to 8%), abdominal pain (7%), diarrhea (6%), xerostomia (6%), dyspepsia (5%), increased appetite (3% to 4%), anorexia (&le;2%), decreased appetite (&le;2%), gastroesophageal reflux disease (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (5% to 7%), dyspnea (2%), rhinorrhea (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, abnormality in thinking, abnormal urinalysis, accidental injury, acne vulgaris, acute coronary syndrome, acute renal failure, aggressive behavior, allergic rhinitis, altered sense of smell, amnesia, anemia, angioedema, arthralgia, asthma, atrial fibrillation, back pain, behavioral changes, Bell palsy, blurred vision, bradycardia, cardiac arrhythmia, cardiac flutter, cataract (subcapsular), cerebrovascular accident, chills, conjunctivitis, cor pulmonale, coronary artery disease, deafness, decreased libido, decreased mental acuity, decreased visual acuity, delusions, diabetes mellitus, difficulty thinking, disorientation, dissociative disorder, dizziness, dysarthria, dysphagia, ECG abnormality, eczema, edema, elevation in serum levels of skeletal-muscle enzymes, emotional disturbance, emotional lability, enterocolitis, epistaxis, equilibrium disturbance, erectile dysfunction, eructation, erythema, erythema multiforme, esophagitis, euphoria, eye irritation, eye pain, fever, flu-like symptoms, flushing, gallbladder disease, gastric ulcer, gastritis, gastrointestinal hemorrhage, hallucination, homicidal ideation, hyperglycemia, hyperhidrosis, hyperlipidemia, hypersensitivity reaction, hypoglycemia, hypokalemia, intestinal obstruction, lack of concentration, leukocytosis, loss of consciousness, lymphadenopathy, mania, Meniere disease, menstrual disease, migraine, multiple sclerosis, muscle cramps, musculoskeletal pain, myalgia, myositis, nephrolithiasis, nocturia, nocturnal amblyopia, nystagmus, ophthalmic vascular disease, oral mucosa ulcer, osteoporosis, palpitations, pancreatitis, panic, paranoia, photophobia, pleurisy, pollakiuria, polyuria, psoriasis, psychomotor agitation, psychomotor retardation, psychosis, pulmonary embolism, respiratory tract disease, restless leg syndrome, seizure, sensory disturbance, sexual difficulty, skin photosensitivity, somnambulism, splenomegaly, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, thrombosis, thyroid disease, tinnitus, toothache, transient blindness, transient ischemic attacks, tremor, upper respiratory tract inflammation, urethral disease, urinary retention, urine abnormality, urticaria, ventricular premature contractions, vertigo, visual field defect, vitreous opacity, weight gain, xeroderma, xerophthalmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975267\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Serious hypersensitivity reactions or skin reactions to varenicline or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975268\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). There have been postmarketing reports of traffic accidents, near-miss incidents in traffic, or other accidental injuries in patients taking varenicline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Postmarketing reports of hypersensitivity reactions (including angioedema) and rare cases of serious skin reactions (including Stevens-Johnson syndrome and erythema multiforme) have been reported. Patients should be instructed to discontinue use and contact healthcare provider if signs/symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nausea: Dose-dependent nausea may occur; both transient and persistent nausea has been reported. Dosage reduction may be considered for intolerable nausea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric effects: Post-marketing cases of serious neuropsychiatric events (including depression, suicidal thoughts, and suicide) have been reported in patients with or without preexisting psychiatric disease; some cases may have been complicated by symptoms of nicotine withdrawal following smoking cessation. Subsequent controlled trials in patients with or without psychiatric disorders; however, have not identified significant differences in neuropsychiatric effects for patients taking varenicline, bupropion, nicotine patches, or placebo (Anthenelli 2013; Anthenelli 2016; Gibbons 2013; Thomas 2015). Monitor all patients for behavioral changes and psychiatric symptoms (eg, agitation, depression, suicidal behavior, suicidal ideation); inform patients to discontinue treatment and contact their health care provider immediately if they experience any behavioral and/or mood changes. Of post-marketing cases, many resolved following therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Somnambulism: Cases of somnambulism, involving harmful behavior to self, others or property, have been reported. Discontinue treatment if somnambulism occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Treatment may increase risk of cardiovascular events. A meta-analysis of 15 clinical trials, including a placebo-controlled trial in patients with stable cardiovascular disease, showed an increased incidence of major cardiovascular events (combined outcome of cardiovascular-related death, nonfatal MI, nonfatal stroke) in patients using varenicline compared with placebo. Cardiovascular events were uncommon in both the varenicline and placebo groups. These findings did not reach statistical significance, although data was consistent. Events occurred primarily in patients with known cardiovascular disease. The meta-analysis also showed a lower incidence of all-cause and cardiovascular mortality in varenicline-treated patients, although this was not statistically significant either.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required with severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures have been reported in patients with or without a history of seizures. Seizures generally occurred within the first month of therapy. Consider the risks against the benefits before initiating in patients with a history of seizures or other factors that can lower the seizure threshold; discontinue use if seizures occur during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300207\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975278\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10339&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Varenicline may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may be decreased and the risk for neuropsychiatric adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May increase the serum concentration of Varenicline. Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicotine: Varenicline may enhance the adverse/toxic effect of Nicotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May increase the serum concentration of Varenicline. Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of Varenicline. Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975264\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16113432\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if varenicline is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975296\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Take after eating and with a full glass of water to decrease gastric upset.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5657064\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for behavioral changes and psychiatric symptoms (eg, agitation, depression, suicidal behavior, suicidal ideation).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975282\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Partial neuronal &alpha;<sub>4</sub> &beta;<sub>2</sub> nicotinic receptor agonist; prevents nicotine stimulation of mesolimbic dopamine system associated with nicotine addiction. Also binds to 5-HT<sub>3</sub> receptor (significance not determined) with moderate affinity. Varenicline stimulates dopamine activity but to a much smaller degree than nicotine does, resulting in decreased craving and withdrawal symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2975284\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed; unaffected by food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &le;20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimal (&lt;10% of clearance is through metabolism)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: ~3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (92% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422182\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Chantix Continuing Month Pak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (56): $352.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Chantix Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (56): $481.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (56): $481.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Chantix Starting Month Pak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 MG X 11 &amp; 1 MG X 42 (53): $481.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4108824\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Champix (AE, AR, AT, AU, BE, BG, BH, BR, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VE, VN, ZW);</li>\n      <li>Chempiks (UA);</li>\n      <li>Varni (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. <i>Lancet</i>. 2016. pii: S0140-6736(16)30272-0. [Epub ahead of print]. doi: 10.1016/S0140-6736(16)30272-0.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/27116918/pubmed\" target=\"_blank\" id=\"27116918\">27116918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. <i>Ann Intern Med</i>. 2013;159(6):390-400. doi: 10.7326/0003-4819-159-6-201309170-00005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/24042367/pubmed\" target=\"_blank\" id=\"24042367\">24042367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Champix (varenicline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; March 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chantix (varenicline) [prescribing information]. New York, NY: Pfizer Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiore M, Jaen CR, Baker TB, et al, &ldquo;A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update. A U.S. Public Health Service Report,&rdquo; <i>Am J Prev Med</i>, 2008, 35(2):158-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/18617085/pubmed\" target=\"_blank\" id=\"18617085\">18617085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. <i>Am J Psychiatry</i>. 2013;170(12):1460-1467. doi: 10.1176/appi.ajp.2013.12121599.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/24030388/pubmed\" target=\"_blank\" id=\"24030388\">24030388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gonzales D, Rennard SI, Nides M, et al, &ldquo;Varenicline, an Alpha4beta2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2006, 296(1):47-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/16820546/pubmed\" target=\"_blank\" id=\"16820546\">16820546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hajek P, McRobbie HJ, Myers KE, et al, &ldquo;Use of Varenicline for 4 Weeks Before Quitting Smoking: Decrease in <i>ad lib</i> Smoking and Increase in Smoking Cessation Rates,&rdquo; <i>Arch Intern Med</i>, 2011, 171(8):770-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/21518946/pubmed\" target=\"_blank\" id=\"21518946\">21518946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henningfield JE, Fant RV, Buchhalter JR, et al, &ldquo;Pharmacotherapy for Nicotine Dependence,&rdquo; <i>CA Cancer J Clin</i>, 2005, 55(5):281-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/16166074/pubmed\" target=\"_blank\" id=\"16166074\">16166074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jorenby DE, Hays JT, Rigotti NA, et al, &ldquo;Efficacy of Varenicline, an Alpha4beta2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2006, 296(1):56-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/16820547/pubmed\" target=\"_blank\" id=\"16820547\">16820547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. <i>BMJ</i>. 2015;350:h1109. doi: 10.1136/bmj.h1109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/25767129/pubmed\" target=\"_blank\" id=\"25767129\">25767129</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tonstad S, Tonneson P, Hajek P, et al, &ldquo;Effect of Maintenance Therapy With Varenicline on Smoking Cessation: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2006, 296(1):64-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varenicline-drug-information/abstract-text/16820548/pubmed\" target=\"_blank\" id=\"16820548\">16820548</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10339 Version 144.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2975238\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4104776\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2975262\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2975291\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2975292\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2975293\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F2975294\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F2975295\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2975300\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2975240\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46146256\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7875058\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2975297\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2975263\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2975271\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2975267\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2975268\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300207\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2975278\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2975264\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16113432\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2975296\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5657064\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2975282\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2975284\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422182\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4108824\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10339|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=varenicline-patient-drug-information\" class=\"drug drug_patient\">Varenicline: Patient drug information</a></li></ul></div></div>","javascript":null}